Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics
Corcept Therapeutics Incorporated (CORT)
Today's Latest Price: $17.18 USD
Updated Jul 2 4:00pm
Add CORT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
CORT Stock Summary
- The ratio of debt to operating expenses for Corcept Therapeutics Inc is higher than it is for about merely 5.97% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.1 for Corcept Therapeutics Inc; that's greater than it is for merely 9.1% of US stocks.
- With a year-over-year growth in debt of 104.6%, Corcept Therapeutics Inc's debt growth rate surpasses 88.01% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Corcept Therapeutics Inc are FORM, CHRS, QLYS, FIT, and LSCC.
- Visit CORT's SEC page to see the company's official filings. To visit the company's web site, go to www.corcept.com.
CORT Stock Price Chart Technical Analysis Charts
CORT Price/Volume Stats
| Current price | $17.18 | 52-week high | $18.52 |
| Prev. close | $17.09 | 52-week low | $9.70 |
| Day low | $16.84 | Volume | 806,142 |
| Day high | $17.49 | Avg. volume | 1,048,585 |
| 50-day MA | $14.81 | Dividend yield | N/A |
| 200-day MA | $13.52 | Market Cap | 1.97B |
Corcept Therapeutics Incorporated (CORT) Company Bio
Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.
CORT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $17.18 | $982.22 | 5799% |
We started the process of determining a valid price forecast for Corcept Therapeutics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Corcept Therapeutics Inc ranked in the 95th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for CORT, they are:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 100. Its equity weight surpasses that of 93.96% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.41% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Corcept Therapeutics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -23.96. This coverage rate is greater than that of only 4.96% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 5684% |
| 1% | 5741% |
| 2% | 5799% |
| 3% | 5857% |
| 4% | 5915% |
| 5% | 5973% |
THC, RDY, DVCR, FVE, and INBP can be thought of as valuation peers to CORT, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...